Benchmark International Successfully Facilitated the Transaction Between Molzym GmbH & Co. KG and Bruker Daltronics GmbH & Co. KG
Benchmark International is pleased to announce the 100% acquisition of Molzym GmbH & Co. KG by Bruker Daltronics GmbH & Co. KG.
Molzym GmbH & Ko. KG, based in Bremen, Germany, is a leading company in biological research and the diagnosis of infectious agents, focusing on the development of new methods and products for the molecular detection of infectious diseases caused by bacteria and fungi. Founded by Prof. Lorenz, the company now sells its kits and reagents in over 30 countries and employs a team of 26 people.
Bruker Daltronics GmbH & Co. KG, headquartered in Bremen, Germany, the company employs over 9,700 people worldwide and provides high-performance scientific instruments and analytical and diagnostic solutions for researching biological and chemical processes at the molecular, cellular and microscopic levels.
With the acquisition of Molzym, Bruker aims to strengthen its presence in biological research and the diagnosis of infectious diseases. The expertise, technology and good reputation are expected to help Bruker continue to grow.
“We are extremely pleased with this successful transaction. In Bruker, we have won a strong and experienced partner. We would also like to express our sincere thanks to everyone involved for their support during the process.” – Dr. Michael Lustig, Managing Director, Molzym GmbH & Co. KG
Benchmark International played a key role in managing the transaction process, from the initial offer through to completion. The team successfully guided the client through the entire process, including a thorough due diligence, ensuring a balanced structure that aligned with the strategic objectives of both parties.
“We are proud to have supported Molzym’s shareholders in securing this strategic acquisition by Bruker. This partnership combines two highly respected biotechnology innovators and positions both companies for continued advancement in molecular diagnostics and life sciences.” – Malte Bockholt, Transaction Lead, Benchmark International